ArticleFrontiers in physiology2026
Correlation of a combined serum biomarker panel with the composite physiologic index in connective tissue disease-associated interstitial lung disease.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The value of serum biomarkers in the management of interstitial lung disease in patients with connective tissue disease: a protocol for an observational study.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the diagnostic performance of a combined serum biomarker panel for connective tissue disease-associated interstitial lung disease (CTD-ILD) and its correlation with disease severity. Methods: This retrospective, cross-sectional study enrolled 200 CTD patients during October 2023 and October 2025, classifying them into CTD-ILD (n = 86) and CTD (n = 114) groups. General clinical characteristics, routine laboratory parameters, serum Krebs von den Lungen-6 (KL-6), surfactant protein A (SP-A), and surfactant protein D (SP-D) levels, serum ferritin (SF), pulmonary function, and the Composite Physiologic Index (CPI) were compared. The predictive power of the biomarker panel was evaluated via receiver operating characteristic (ROC) curves and DeLong's test, while correlations with the CPI were assessed via Spearman's correlation analysis. Results: The groups were comparable in baseline characteristics and routine laboratory parameters. The CTD-ILD group exhibited significantly higher levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and all four serum biomarkers (KL-6, SP-A, SP-D, and SF) (all Conclusion: The combined serum biomarker panel demonstrated strong discrimination for CTD-ILD in this retrospective cohort and was significantly associated with disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.